ExoCounter Assays Identify Women Who May Develop Early-Onset Preeclampsia From 12.5 μL First-Trimester Serum by Characterizing Placental Small Extracellular Vesicles.

Shuhan Jiang Wei ZhangQing CaoMaryam RahbarWilliam R Cooke Masayuki OnoKenichi FujimakiAtsushi SaitoMakoto ItonagaKenta OdaChristopher RedmanManu Vatish

Published in: Hypertension (Dallas, Tex. : 1979) (2023)

Application of the ExoCounter assay developed here could identify patients at risk of developing EOPE in the first trimester, thereby providing a window of opportunity for early intervention.

Keyphrases

early onset
late onset
high throughput
randomized controlled trial
polycystic ovary syndrome
pregnancy outcomes
type diabetes
adipose tissue
breast cancer risk
skeletal muscle